Do I need a prescription for Mianserin 10mg tablets?

Mianserin 10mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Mianserin 10mg tablets?

Mianserin 10mg tablets is the generic name. It is available under brand names including: Mianserin 10mg tablets, Mianserin 10mg tablets, Mianserin 10mg tablets, Mianserin 10mg tablets, Mianserin 10mg tablets and 4 more. (Source: NHS dm+d — Actual Medicinal Products)

Mianserin 10mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

10mg

Oral

A tetracyclic compound with antidepressant effects.

Active ingredients:

Mianserin

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 04.03.01

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC N06AX03

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Mianserin

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Mianserin

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Mianserin

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Mianserin

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

9 branded products available

9 productsShow details

9 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Mianserin on the MHRA register

Mianserin 10mg tablets

A A H Pharmaceuticals Ltd

Mianserin 10mg tablets

Viatris UK Healthcare Ltd

Mianserin 10mg tablets

Alliance Healthcare (Distribution) Ltd

Mianserin 10mg tablets

Actavis UK Ltd

Discontinued

Mianserin 10mg tablets

Teva UK Ltd

Discontinued

Mianserin 10mg tablets

Kent Pharma (UK) Ltd

Discontinued

Mianserin 10mg tablets

DE Pharmaceuticals

Discontinued

Mianserin 10mg tablets

Mawdsley-Brooks & Company Ltd

Discontinued

Mianserin 10mg tablets

Imported

None

Discontinued

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Price & daily doseShow details

£19.56indicative price

This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.

View full Drug Tariff

Source: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.

WHO defined daily dose (DDD)

60 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Venlafaxine 37.5mg/5ml oral solution sugar free

Oral solution

37.5mg/5ml

Same therapeutic group

Venlafaxine 75mg/5ml oral solution sugar free

Oral solution

75mg/5ml

Same therapeutic group

Duloxetine 90mg gastro-resistant capsules

Capsule

90mg

Same therapeutic group

Duloxetine 120mg gastro-resistant capsules

Capsule

120mg

Same therapeutic group

Esketamine 28mg/0.2ml nasal spray unit dose

Spray

28mg/0.2ml

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Mianserin

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(1)

Depression in adults with a chronic physical health problem: recognition and management (CG91)

CG91

Clinical guideline

Updated Oct 2009

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Mianserin

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

42274111000001108

dm+d ID

42274111000001108

VTM (Virtual Therapeutic Moiety)

776779000

VMP (Virtual Medicinal Product)

42274111000001108

BNF code

04030100

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

N06AX03

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

17 found

Half-life

10-17 hours

Mechanism

Mianserin's mechanism of therapeutic action is not well understood, although it…

Food interactions

None known

Human targets

20 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

Absorbed following oral administration.

Half-life

10-17 hours

10-17 hours

Protein binding

90%

Metabolism

Hepatic.

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Withdrawn

Small molecule

About this compound

A tetracyclic compound with antidepressant effects. Mianserin was previously available internationally, however in most markets it has been phased out in favour of [mirtazapine].

Properties:

solid

Avg. mass: 264.36 Da

DrugBank indication

For the treatment of depression.

Also known as(138)

1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine

Mianserin

Mianserina

Mianserine

Miansérine

Mianserinum

Mianseryna

ADRA2R

Dosage forms(8)

Solution / drops (Oral) — 60 MG/ML

Tablet (Oral) — 20 MG

Tablet, film coated (Oral) — 60 MG

Tablet (Oral) — 30.000 mg

Tablet (Oral) — 10 mg

Tablet (Oral) — 30 mg

Tablet, film coated (Oral) — 30 mg

Tablet, film coated (Oral) — 10 mg

Molecular properties(18)

Drug interactions(1557)

Known interactions with other medications. Always consult a healthcare professional.

Deferasirox

Unknown severity

DB01609

The serum concentration of Mianserin can be increased when it is combined with Deferasirox.

Check this interaction

Peginterferon alfa-2b

Unknown severity

DB00022

The serum concentration of Mianserin can be increased when it is combined with Peginterferon alfa-2b.

Check this interaction

Leflunomide

Unknown severity

DB01097

The serum concentration of Mianserin can be decreased when it is combined with Leflunomide.

Check this interaction

Teriflunomide

Unknown severity

DB08880

The serum concentration of Mianserin can be decreased when it is combined with Teriflunomide.

Check this interaction

Valsartan

Moderate

DB00177

Mianserin may decrease the antihypertensive activities of Valsartan.

Check this interaction

Ramipril

Moderate

DB00178

Mianserin may decrease the antihypertensive activities of Ramipril.

Check this interaction

Remikiren

Moderate

DB00212

Mianserin may decrease the antihypertensive activities of Remikiren.

Check this interaction

Torasemide

Moderate

DB00214

Mianserin may decrease the antihypertensive activities of Torasemide.

Check this interaction

Guanadrel

Moderate

DB00226

Mianserin may decrease the antihypertensive activities of Guanadrel.

Check this interaction

Olmesartan

Moderate

DB00275

Mianserin may decrease the antihypertensive activities of Olmesartan.

Check this interaction

Chlorthalidone

Moderate

DB00310

Mianserin may decrease the antihypertensive activities of Chlorthalidone.

Check this interaction

Nitroprusside

Moderate

DB00325

Mianserin may decrease the antihypertensive activities of Nitroprusside.

Check this interaction

Minoxidil

Moderate

DB00350

Mianserin may decrease the antihypertensive activities of Minoxidil.

Check this interaction

Treprostinil

Moderate

DB00374

Mianserin may decrease the antihypertensive activities of Treprostinil.

Check this interaction

Bendroflumethiazide

Moderate

DB00436

Mianserin may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Prazosin

Moderate

DB00457

Mianserin may decrease the antihypertensive activities of Prazosin.

Check this interaction

Fosinopril

Moderate

DB00492

Mianserin may decrease the antihypertensive activities of Fosinopril.

Check this interaction

Trandolapril

Moderate

DB00519

Mianserin may decrease the antihypertensive activities of Trandolapril.

Check this interaction

Metolazone

Moderate

DB00524

Mianserin may decrease the antihypertensive activities of Metolazone.

Check this interaction

Benazepril

Moderate

DB00542

Mianserin may decrease the antihypertensive activities of Benazepril.

Check this interaction

Cyclothiazide

Moderate

DB00606

Mianserin may decrease the antihypertensive activities of Cyclothiazide.

Check this interaction

Candoxatril

Moderate

DB00616

Mianserin may decrease the antihypertensive activities of Candoxatril.

Check this interaction

Mecamylamine

Moderate

DB00657

Mianserin may decrease the antihypertensive activities of Mecamylamine.

Check this interaction

Moexipril

Moderate

DB00691

Mianserin may decrease the antihypertensive activities of Moexipril.

Check this interaction

Lisinopril

Moderate

DB00722

Mianserin may decrease the antihypertensive activities of Lisinopril.

Check this interaction

Nitroglycerin

Moderate

DB00727

Mianserin may decrease the antihypertensive activities of Nitroglycerin.

Check this interaction

Hydroflumethiazide

Moderate

DB00774

Mianserin may decrease the antihypertensive activities of Hydroflumethiazide.

Check this interaction

Cryptenamine

Moderate

DB00785

Mianserin may decrease the antihypertensive activities of Cryptenamine.

Check this interaction

Perindopril

Moderate

DB00790

Mianserin may decrease the antihypertensive activities of Perindopril.

Check this interaction

Candesartan cilexetil

Moderate

DB00796

Mianserin may decrease the antihypertensive activities of Candesartan cilexetil.

Check this interaction

Fenoldopam

Moderate

DB00800

Mianserin may decrease the antihypertensive activities of Fenoldopam.

Check this interaction

Eprosartan

Moderate

DB00876

Mianserin may decrease the antihypertensive activities of Eprosartan.

Check this interaction

Chlorothiazide

Moderate

DB00880

Mianserin may decrease the antihypertensive activities of Chlorothiazide.

Check this interaction

Quinapril

Moderate

DB00881

Mianserin may decrease the antihypertensive activities of Quinapril.

Check this interaction

Telmisartan

Moderate

DB00966

Mianserin may decrease the antihypertensive activities of Telmisartan.

Check this interaction

Hydrochlorothiazide

Moderate

DB00999

Mianserin may decrease the antihypertensive activities of Hydrochlorothiazide.

Check this interaction

Trichlormethiazide

Moderate

DB01021

Mianserin may decrease the antihypertensive activities of Trichlormethiazide.

Check this interaction

Deserpidine

Moderate

DB01089

Mianserin may decrease the antihypertensive activities of Deserpidine.

Check this interaction

Pentolinium

Moderate

DB01090

Mianserin may decrease the antihypertensive activities of Pentolinium.

Check this interaction

Trimethaphan

Moderate

DB01116

Mianserin may decrease the antihypertensive activities of Trimethaphan.

Check this interaction

Diazoxide

Moderate

DB01119

The metabolism of Mianserin can be decreased when combined with Diazoxide.

Check this interaction

Bretylium

Moderate

DB01158

Mianserin may decrease the antihypertensive activities of Bretylium.

Check this interaction

Terazosin

Moderate

DB01162

Mianserin may decrease the antihypertensive activities of Terazosin.

Check this interaction

Epoprostenol

Moderate

DB01240

Mianserin may decrease the antihypertensive activities of Epoprostenol.

Check this interaction

Polythiazide

Moderate

DB01324

Mianserin may decrease the antihypertensive activities of Polythiazide.

Check this interaction

Cilazapril

Moderate

DB01340

Mianserin may decrease the antihypertensive activities of Cilazapril.

Check this interaction

Saprisartan

Moderate

DB01347

Mianserin may decrease the antihypertensive activities of Saprisartan.

Check this interaction

Spirapril

Moderate

DB01348

Mianserin may decrease the antihypertensive activities of Spirapril.

Check this interaction

Dexpropranolol

Moderate

DB03322

Mianserin may decrease the antihypertensive activities of Dexpropranolol.

Check this interaction

Tienilic acid

Moderate

DB04831

Mianserin may decrease the antihypertensive activities of Tienilic acid.

Check this interaction

Showing 50 of 1557 interactions

Toxicity & overdose

Oral rat LD₅₀: 780mg/kg

How it works

Mechanism of action

Mianserin's mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.

Pharmacodynamics

Mianserin is a tetracyclic antidepressant that has antihistaminic and hypnosedative, but almost no anticholinergic, effect. It is a weak inhibitor of norepinephrine reuptake and strongly stimulates the release of norepinephrine. Interactions with serotonin receptors in the central nervous system have also been found. Its effect is usually noticeable after one to three weeks. Mianserin may cause drowsiness and hematological problems.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Absorbed following oral administration.

Half-life

10-17 hours

Protein binding

90%

Metabolism

Hepatic.

Drug targets(20)

Proteins and enzymes this drug interacts with in the body

Alpha-2A adrenergic receptor

BE0000289

ADRA2A

antagonist

Specific functionalpha-1B adrenergic receptor binding

Cellular location

Cell membrane

General function & pharmacology

Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol

5-hydroxytryptamine receptor 2A

BE0000451

HTR2A

antagonist

Specific function1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin) .
PMID:1330647 PMID:18703043 PMID:19057895 PMID:21645528 PMID:22300836 PMID:35084960 PMID:38552625

Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD) .
PMID:28129538 PMID:35084960
Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors .
PMID:28129538 PMID:35084960
HTR2A is coupled to G(q)/G(11) G alpha proteins and activates phospholipase C-beta, releasing diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) second messengers that modulate the activity of phosphatidylinositol 3-kinase and promote the release of Ca(2+) ions from intracellular stores, respectively .
PMID:18703043 PMID:28129538 PMID:35084960

Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways .
PMID:28129538 PMID:35084960
Affects neural activity, perception, cognition and mood .
PMID:18297054
Plays a role in the regulation of behavior, including responses to anxiogenic situations and psychoactive substances. Plays a role in intestinal smooth muscle contraction, and may play a role in arterial vasoconstriction (By similarity)

5-hydroxytryptamine receptor 2C

BE0000533

HTR2C

antagonist

Specific function1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin) .
PMID:12970106 PMID:18703043 PMID:19057895 PMID:29398112 PMID:7895773

Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD) .
PMID:19057895 PMID:29398112
Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors .
PMID:18703043 PMID:29398112
HTR2C is coupled to G(q)/G(11) G alpha proteins and activates phospholipase C-beta, releasing diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) second messengers that modulate the activity of phosphatidylinositol 3-kinase and promote the release of Ca(2+) ions from intracellular stores, respectively .
PMID:18703043 PMID:29398112
Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways .
PMID:29398112
Regulates neuronal activity via the activation of short transient receptor potential calcium channels in the brain, and thereby modulates the activation of pro-opiomelanocortin neurons and the release of CRH that then regulates the release of corticosterone (By similarity). Plays a role in the regulation of appetite and eating behavior, responses to anxiogenic stimuli and stress (By similarity). Plays a role in insulin sensitivity and glucose homeostasis (By similarity)

Histamine H1 receptor

BE0000442

HRH1

antagonist

Specific functionhistamine receptor activity

Cellular location

Cell membrane

General function & pharmacology

G-protein-coupled receptor for histamine, a biogenic amine that functions as an immune modulator and a neurotransmitter .
PMID:33828102 PMID:8280179
Through the H1 receptor, histamine mediates the contraction of smooth muscles and increases capillary permeability due to contraction of terminal venules. Also mediates neurotransmission in the central nervous system and thereby regulates circadian rhythms, emotional and locomotor activities as well as cognitive functions (By similarity)

Sodium-dependent noradrenaline transporter

BE0000486

SLC6A2

inhibitor

Specific functionactin binding

Cellular location

Cell membrane

General function & pharmacology

Mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline), the primary signaling neurotransmitter in the autonomic sympathetic nervous system .
PMID:2008212 PMID:8125921 PMID:38750358

Is responsible for norepinephrine re-uptake and clearance from the synaptic cleft, thus playing a crucial role in norepinephrine inactivation and homeostasis (By similarity). Can also mediate sodium- and chloride-dependent transport of dopamine PMID:11093780 PMID:8125921 PMID:39395208 PMID:39048818

Metabolizing enzymes(4)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP1A2Cytochrome P450 1A2

substrate

CYP2B6Cytochrome P450 2B6

substrate

CYP2D6Cytochrome P450 2D6

substrate

CYP3A4Cytochrome P450 3A4

substrate

Scientific references(5)

Koyama E., Chiba K., Tani M., Ishizaki T.

Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers..

The Journal of Pharmacology and Experimental Therapeutics

1996278(1):21-30. doi: 10.1016/s0022-3565(25)20103-3

PMID: 8764331 DOI: 10.1016/s0022-3565(25)20103-3

de Boer T.H., Nefkens F., van Helvoirt A., van Delft A.M.

Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan..

The Journal of Pharmacology and Experimental Therapeutics

1996277(2):852-860. doi: 10.1016/s0022-3565(25)12943-1

PMID: 8627567 DOI: 10.1016/s0022-3565(25)12943-1

Kelder J., Funke C., De Boer T., Delbressine L., Leysen D., Nickolson V.

A Comparison of the Physicochemical and Biological Properties of Mirtazapine and Mianserin.

Journal of Pharmacy and Pharmacology

199749(4):403-411. doi: 10.1111/j.2042-7158.1997.tb06814.x

PMID: 9232538 DOI: 10.1111/j.2042-7158.1997.tb06814.x

Petrie W.M., Wilson W.H., Ban T.A., Guy W., Schaffer J.D.

Mianserin: determination of therapeutic dose range.

International Pharmacopsychiatry

198015(2):111-7. doi: 10.1159/000468421

PMID: 7002830 DOI: 10.1159/000468421

Brogden R.N., Heel R.C., Speight T.M., Avery G.S.

Mianserin: a review of its pharmacological properties and therapeutic efficacy in depressive illness.

Drugs

1978 Oct16(4):273-301. doi: 10.2165/00003495-197816040-00001

PMID: 359311 DOI: 10.2165/00003495-197816040-00001

ATC classification(1 code)

ATC N06AX03

Affected organisms(1)

Humans and other mammals

International brands(6)

Salt forms(1)

Mianserin hydrochloride(DBSALT000957)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Mianserin

DB06148

CAS number

24219-97-4

UNII (FDA)

250PJI13LM

InChI Key (molecular fingerprint)

UEQUQVLFIPOEMF-UHFFFAOYSA-N

Additional database identifiers

ChEBI

51137

PubChem Compound

4184

PubChem Substance

46508096

ChemSpider

4040

BindingDB

50222218

PharmGKB

PA134687937

Therapeutic Targets Database

DAP000293

IUPHAR

135

Guide to Pharmacology

135

Wikipedia

Mianserin

ChEMBL

CHEMBL6437

RxCUI

6929

HUGO Gene Nomenclature Committee (HGNC)

HGNC:281

GenAtlas

ADRA2A

GeneCards

ADRA2A

GenBank Gene Database

M23533

GenBank Protein Database

178196

IUPHAR

Guide to Pharmacology

UniProtKB

P08913

UniProt Accession

ADA2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5293

GenAtlas

HTR2A

GeneCards

HTR2A

GenBank Gene Database

S42168

GenBank Protein Database

36431

IUPHAR

Guide to Pharmacology

UniProtKB

P28223

UniProt Accession

5HT2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5295

GenAtlas

HTR2C

GeneCards

HTR2C

GenBank Gene Database

M81778

GenBank Protein Database

338028

IUPHAR

Guide to Pharmacology

UniProtKB

P28335

UniProt Accession

5HT2C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5182

GenAtlas

HRH1

GeneCards

HRH1

GenBank Gene Database

Z34897

GenBank Protein Database

510296

IUPHAR

262

Guide to Pharmacology

262

UniProtKB

P35367

UniProt Accession

HRH1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11048

GenAtlas

SLC6A2

GeneCards

SLC6A2

GenBank Gene Database

M65105

GenBank Protein Database

189258

Guide to Pharmacology

926

UniProtKB

P23975

UniProt Accession

SC6A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11050

GenAtlas

SLC6A4

GeneCards

SLC6A4

GenBank Gene Database

X70697

GenBank Protein Database

36433

Guide to Pharmacology

928

UniProtKB

P31645

UniProt Accession

SC6A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:17383

GenAtlas

HRH4

GeneCards

HRH4

GenBank Gene Database

AB044934

GenBank Protein Database

10241847

IUPHAR

265

Guide to Pharmacology

265

UniProtKB

Q9H3N8

UniProt Accession

HRH4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5286

GenAtlas

HTR1A

GeneCards

HTR1A

GenBank Gene Database

M28269

GenBank Protein Database

189928

IUPHAR

Guide to Pharmacology

UniProtKB

P08908

UniProt Accession

5HT1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:283

GenAtlas

ADRA2C

GeneCards

ADRA2C

GenBank Gene Database

J03853

GenBank Protein Database

178194

IUPHAR

Guide to Pharmacology

UniProtKB

P18825

UniProt Accession

ADA2C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5294

GenAtlas

HTR2B

GeneCards

HTR2B

GenBank Gene Database

X77307

GenBank Protein Database

475198

IUPHAR

Guide to Pharmacology

UniProtKB

P41595

UniProt Accession

5HT2B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5292

GenAtlas

HTR1F

GeneCards

HTR1F

GenBank Gene Database

L05597

GenBank Protein Database

307420

IUPHAR

Guide to Pharmacology

UniProtKB

P30939

UniProt Accession

5HT1F_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:282

GenAtlas

ADRA2B

GeneCards

ADRA2B

GenBank Gene Database

M34041

GenBank Protein Database

178198

IUPHAR

Guide to Pharmacology

UniProtKB

P18089

UniProt Accession

ADA2B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3024

GenAtlas

DRD3

GeneCards

DRD3

GenBank Gene Database

U32499

GenBank Protein Database

927342

IUPHAR

216

Guide to Pharmacology

216

UniProtKB

P35462

UniProt Accession

DRD3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:8154

GenAtlas

OPRK1

GeneCards

OPRK1

GenBank Gene Database

U11053

GenBank Protein Database

532060

IUPHAR

318

Guide to Pharmacology

318

UniProtKB

P41145

UniProt Accession

OPRK_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11049

GenAtlas

SLC6A3

GeneCards

SLC6A3

GenBank Gene Database

M96670

GenBank Protein Database

553260

Guide to Pharmacology

927

UniProtKB

Q01959

UniProt Accession

SC6A3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5302

GenAtlas

HTR7

GeneCards

HTR7

GenBank Gene Database

U68487

GenBank Protein Database

1857143

IUPHAR

Guide to Pharmacology

UniProtKB

P34969

UniProt Accession

5HT7R_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3023

GenAtlas

DRD2

GeneCards

DRD2

GenBank Gene Database

M30625

GenBank Protein Database

181432

IUPHAR

215

Guide to Pharmacology

215

UniProtKB

P14416

UniProt Accession

DRD2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5301

GenAtlas

HTR6

GeneCards

HTR6

GenBank Gene Database

L41147

GenBank Protein Database

1162924

IUPHAR

Guide to Pharmacology

UniProtKB

P50406

UniProt Accession

5HT6R_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:277

GenAtlas

ADRA1A

GeneCards

ADRA1A

GenBank Gene Database

D25235

GenBank Protein Database

433201

IUPHAR

Guide to Pharmacology

UniProtKB

P35348

UniProt Accession

ADA1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:278

GenAtlas

ADRA1B

GeneCards

ADRA1B

GenBank Gene Database

M99589

IUPHAR

Guide to Pharmacology

UniProtKB

P35368

UniProt Accession

ADA1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:280

GenAtlas

ADRA1D

GeneCards

ADRA1D

GenBank Gene Database

M76446

GenBank Protein Database

177807

IUPHAR

Guide to Pharmacology

UniProtKB

P25100

UniProt Accession

ADA1D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3020

GenAtlas

DRD1

GeneCards

DRD1

GenBank Gene Database

X55760

GenBank Protein Database

30397

IUPHAR

214

Guide to Pharmacology

214

UniProtKB

P21728

UniProt Accession

DRD1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3026

GenAtlas

DRD5

GeneCards

DRD5

GenBank Gene Database

X58454

GenBank Protein Database

32049

IUPHAR

218

Guide to Pharmacology

218

UniProtKB

P21918

UniProt Accession

DRD5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2596

GenAtlas

CYP1A2

GeneCards

CYP1A2

GenBank Gene Database

Z00036

Guide to Pharmacology

1319

UniProtKB

P05177

UniProt Accession

CP1A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2615

GeneCards

CYP2B6

GenBank Gene Database

M29874

GenBank Protein Database

181296

Guide to Pharmacology

1324

UniProtKB

P20813

UniProt Accession

CP2B6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 26 days ago(8 Mar 2026)

Back to medicines

Mianserin 10mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

NICE clinical guidance(1)

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Metabolism

Clinical essentials

Pharmacology

Deep science
24

Chemical identifiers

Mianserin

Additional database identifiers

DrugBank citations

Mianserin 10mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

NICE clinical guidance(1)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Metabolism

Clinical essentials

Pharmacology

Deep science24

Chemical identifiers

Mianserin

Additional database identifiers

DrugBank citations

Deep science
24